Promethazine w. Codeine CV
Generic Name and Formulations:
Codeine phosphate 10mg, promethazine HCl 6.25mg; per 5mL; syrup; contains alcohol 7%.
Various generic manufacturers
Indications for Promethazine w. Codeine:
Cough and upper respiratory symptoms associated with allergy or common cold.
Use lowest effective dose for shortest duration. Use accurate measuring device. ≥12yrs: 5mL every 4–6hrs; max 30mL/24hrs.
<12yrs: see Contraindications.
Children <12yrs. Post-op management in children <18yrs following tonsillectomy and/or adenoidectomy. Coma. Lower respiratory disorders. Asthma.
Risk of life-threatening respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. in children for post-tonsillectomy and/or adenoidectomy pain). Avoid in adolescents 12–18yrs with conditions associated with hypoventilation (eg, post-op status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, concomitant drugs that cause respiratory depression). Head injury, intracranial lesions or pre-existing increase in intracranial pressure. Avoid in chronic respiratory disease, acute febrile illness with productive cough, compromised respiratory function (eg, COPD, sleep apnea). Discontinue if neuroleptic malignant syndrome (NMS) occurs. Seizure disorders. Bone marrow depression. Acute abdomen. Fever. Hypothyroidism. Addison's disease. Ulcerative colitis. Prostatic hypertrophy. Recent GI or urinary tract surgery. Narrow-angle glaucoma. Stenosing peptic ulcer. Pyloroduodenal or bladder-neck obstruction. Dehydration. Avoid prolonged sun exposure. Severe hepatic or renal impairment. Ultra-rapid metabolizers (due to CYP2D6 polymorphism): avoid. Atopic children. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antitussive + antihistamine.
Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. Concomitant epinephrine: not recommended. Increased risk of NMS with concomitant antipsychotics. Caution with anticholinergics. Increased extrapyramidal effects with MAOIs. Concomitant narcotics, local anesthetics: may lower seizure threshold. May alter hCG pregnancy test and glucose tolerance test results.
Drowsiness, CNS or respiratory depression, constipation, anticholinergic effects, orthostatic hypotension, photosensitivity, paradoxical excitement, changes in blood pressure, convulsions, jaundice, blood dyscrasias.
Formerly known under the brand name Phenergan with Codeine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML